Aprea Therapeutics Inc (APRE)
Aprea Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapies based on synthetic lethality and DNA damage response pathways. The company’s pipeline includes APR-1051, an orally available small-molecule WEE1 kinase inhibitor being evaluated in a Phase 1 study for patients with advanced solid tumors with biomarkers, and ATRN-119, an ATR inhibitor in Phase 1/2a testing for solid tumor indications. Aprea Therapeutics is headquartered in Doylestown, Pennsylvania. Its common stock is listed on the NASDAQ exchange under the symbol APRE.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-APRE
|
$1.01
|
41.9% Upside
|
Undervalued
|
$4.30
|
505.6% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-0.7x
|
0.2x
|
71.3x
|
8.284 M
|
-36.947 M
|
0.0%
|
59.8%
|
-7.4
|
—
|
100.5%
|
